Plasma markers of platelet and polymorphonuclear leukocyte activation in young adults with acute myocardial infarction.
Our goal was to evaluate some plasma markers of platelet and polymorphonuclear leukocyte (PMN) activation in a group of young adults with acute myocardial infarction (AMI) at the initial stage and after three months. We enrolled 49 AMI subjects aged<45 years and examined plasmatic levels of platelet factor 4 (PF4), beta-thromboglobulin (beta-TG), elastase and myeloperoxidase (MPO) using ELISA methods. PF4 and beta-TG were increased, compared to control subjects, both at the initial stage and after 3 months. In control subjects and in AMI patients, at both times of observation, there was a significant and positive correlation between the two platelet parameters, while no correlation was present between each parameter and platelet count. In AMI patients there was an increase in elastase levels in comparison with the control group; this increase was evident at the initial stage and after 3 months. There was no difference in MPO levels between control subjects and AMI patients. In control subjects and in AMI patients there was a significant and positive correlation between elastase and MPO level, whereas no relationship was found between each marker and PMN count. Our data show that in young AMI patients the discharge treatment including antiplatelet drugs did not modify platelet activation and suggest the association of molecules able to inhibit PMN activation to the conventional therapy of these AMI patients.
Caimi
Gregorio
G
Dipartimento di Medicina Interna, Malattie Cardiovascolari e Nefrourologiche, Università di Palermo, Palermo, Italy. caimigre@unipa.it
Hoffmann
Enrico
E
Montana
Maria
M
Incalcaterra
Egle
E
Dispensa
Flavia
F
D'Amico
Teresa
T
Canino
Baldassare
B
Lo Presti
Rosalia
R
D000328:Adult; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy; D018375:Neutrophil Activation / Q000187:drug effects*; D010196:Pancreatic Elastase / Q000032:analysis; D009195:Peroxidase / Q000032:analysis; D015539:Platelet Activation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D010978:Platelet Factor 4 / Q000032:analysis; D001620:beta-Thromboglobulin / Q000032:analysis
D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors; D001620:beta-Thromboglobulin; D010978:Platelet Factor 4; D009195:Peroxidase; D010196:Pancreatic Elastase